How is the eurozone crisis hitting pharma and what are the risks?
This article was originally published in Scrip
This time last year, the idea that a eurozone country might have to abandon the currency was a fairly outlandish one. But the tumult of the past 12 months has seen old certainties dissolve, and even if it is still generally thought that such an eventuality is unlikely, the means of avoiding it are far from decided and the risk is real. So real, in fact, that in Deloitte's most recent survey of UK CFOs, the risk of a break-up of the euro was their biggest single worry.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.